BioCentury
ARTICLE | Clinical News

AZ's anifrolumab misses in Phase III for lupus

September 7, 2018 4:41 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) and its MedImmune LLC unit said anifrolumab (formerly MEDI-546) missed the primary endpoint in the Phase III TULIP 1 trial to treat systemic lupus erythematosus (SLE). Compared with placebo, anifrolumab failed to significantly reduce disease activity as measured by the SLE Responder Index (SRI)-4 response at 12 months.

The double-blind, international trial enrolled 460 patients with moderately to severely active autoantibody-positive SLE who were receiving standard of care (SOC) to receive placebo or 150 or 300 mg IV anifrolumab every four weeks. Anifrolumab is a human mAb targeting type I interferon (IFN) receptor 1...

BCIQ Company Profiles

AstraZeneca plc